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Abstract
Background: Amyotrophic lateral sclerosis (ALS) is an incurable neurodegenerative disease that dramatically affects
patients’ quality of life (QoL) and dignity of life (DoL). We aimed to study the impact of ALS on QoL and DoL and
how these evolve throughout the duration of the disease.
Methods: First, we performed an observational, descriptive study of 43 patients with ALS recruited from the ALS
unit at our center and compared them with 20 healthy age- and sex-matched controls. Second, we performed a
prospective cohort study, following up 23 patients with ALS over 3 months. All participants completed questionnaires
about their functional status, QoL, and DoL.
Results: QoL and DoL were significantly worse in the ALS group than in controls (both p< 0.001). During the three-month
follow-up in the ALS cohort, statistically significant declines were observed in clinical status and QoL. For clinical status,
median scores on the ALS Functional Rating scale changed from 30.95 points at baseline to 27.24 points after 3 months
(p = 0.0003). For QoL, median scores on the ALS Assessment Questionnaire changed from 124.19 points at baseline to
131.81 at 3 months (p= 0.0062). However, no significant differences were found between the DoL scores at baseline (48.
14 points) and 3 months (45 points) (p-value = 0.12).
Conclusions: ALS is a neurodegenerative disease that affects QoL and DoL alike. We found that clinical status and QoL both
deteriorated in patients with ALS as the disease progressed, but that DoL was preserved. However, our findings are limited by
small sample sizes. The preservation of DoL may be due to multiple factors, including the therapies provided by the ALS unit.
These findings suggest that alongside QoL, DoL may be an important target in the management and care of ALS patients.
Background
Amyotrophic lateral sclerosis (ALS) is a fatal disease
characterized by progressive degeneration of motor neu-
rons in the brain and spinal cord [1]. The loss of motor
neurons leads to progressive weakness that mainly im-
pairs voluntary motor function, including that associated
with walking, swallowing, speaking, and/or breathing.
ALS may also cause severe cognitive and behavioral
impairment such as frontotemporal dementia [2].
In clinical practice, ALS can be classified as spinal, bulbar,
or respiratory depending on the location of the motor neu-
rons affected at the onset of the disease. Patients with spinal
onset typically develop problems with upper or lower limb
mobility in the form of muscle weakness and cramps. In
patients with bulbar onset, the initial symptoms are usually
dysphagia and/or dysarthria, while in patients with respira-
tory onset, the initial symptom is usually dyspnea or even
acute respiratory failure [3, 4].
ALS typically affects people aged 40–70 years old, and
most patients (around 60%) are men. The annual incidence
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among Europeans is 2–3 per 100,000 in the general popula-
tion [4]. However, variations are found in different parts of
the continent, possibly due to environmental and/or genetic
factors [5]. Although the contribution of environmental fac-
tors remains unclear, major advances have been made in
our understanding of the genetic causes of ALS [4]. For
instance, a better understanding of the roles of disturbed
RNA metabolism and pathological protein aggregation has
given new hope that novel diagnostic and therapeutic
approaches can be developed [5].
Older age, male sex, family history of ALS, and bulbar
onset are consistently reported as markers of poor prog-
nosis. By contrast, low rates of symptom progression,
better psychosocial factors, and better respiratory func-
tion are all associated with better outcomes. The effect
on survival of enteral nutrition by percutaneous endo-
scopic gastrostomy (PEG) is unclear, but it has been
shown that bi-level positive airway pressure (BPAP) and
riluzole therapy can slightly improve survival (the latter
by 3–6 months) [5].
Unfortunately, there is no cure for ALS at present, and
the disease is normally fatal within 20 to 48 months
from onset, although 10%–20% of patients with ALS sur-
vive longer than 10 years. The cause of death is normally
respiratory insufficiency or aspiration pneumonia [6].
Since it is a degenerative disease without either a bio-
logical marker or curative treatment, diagnosis is based
on the exclusion of diseases with similar clinical findings
by effective treatment, coupled with evidence of upper
and lower motor neurons being affected at multiple
levels. To facilitate diagnosis, a number of diagnostic cri-
teria have been developed, with the El Escorial criteria
being the most widely used [7]. Due to the continued
lack of an effective treatment for ALS, therapy focuses
on symptom control and palliative care, aiming to main-
tain quality of life (QoL) as high as possible [5].
The ALS Functional Rating (ALSFR) scale is com-
monly used to assess physical symptom progression [8].
This is a validated questionnaire-based scale that mea-
sures physical functioning while patients with ALS carry
out activities of daily living. The scale components are
grouped into four domains: gross motor tasks, fine
motor tasks, bulbar functions, and respiratory function.
The scale ranges from 0 to 40, where lower scores indi-
cate poorer function.
The meaning of QoL is difficult to describe because
it encompasses objective and subjective indicators, a
broad range of life domains, and individual values. A
QoL assessment should not apply externally derived
norms without reference to individual differences, and
should allow objective comparisons to be made be-
tween the situations of specific groups and what is
considered normal [8]. Standard indicators of QoL are
wealth, employment, residence, physical and mental
health, education, recreation and leisure time, and social
belonging [9].
Given that physical and mental health are major factors
in the evaluation of QoL, healthcare professionals must
take these into account when planning therapeutic inter-
ventions. However, specialists frequently focus on resolv-
ing a specific pathology with aggressive therapy that can
actually worsen the patient’s QoL and global functionality
over the medium or long term. QoL is severely and pro-
gressively affected in patients with ALS [9], and health
professionals have a duty to preserve it whenever possible
[10]. The ALS Assessment Questionnaire (ALSAQ40) can
be used to measure the subjective wellbeing of patients
with ALS [11, 12] across five domains (physical mobility,
activities of daily living and independence, eating and
drinking, communication, and emotional reactions) over
the last 2 weeks. The maximum score is 200 points, with
higher scores indicating lower QoL [12].
Human dignity can be described as the ability to exercise
free will and choice. Consequently, the concept of dignity
of life (DoL) is intimately associated with the principle of
autonomy in biomedical ethics: that is, it is always the
patient who decides and who has the final say [13, 14]. One
of the first studies to explore dignity therapy in people with
ALS indicated that the end of life experience could be
enhanced by supporting the unique identity of a person
and by helping family members during bereavement [15].
The Patient Dignity Inventory (PDI) is a useful instrument
for measuring DoL [13, 14]. This novel screening tool
assesses multiple sources of distress salient to patients with
limited life expectancies on a scale from 25 to 125, with
higher scores indicating greater distress. It is a reliable, vali-
dated measure that has been derived from empirical studies
on dignity concerns among the terminally ill [16–18].
Moreover, the questionnaire has been validated in multiple
languages and applied in palliative care settings and studies
worldwide. One national study of patients with cancer indi-
cated that the PDI readily helped identify dignity-related
distress in 76% of cases in which clinicians were previously
unaware of distress, thereby allowing timely and targeted
therapeutic responses [18, 19].
In the first part of this two-step study, we aimed to
determine how ALS affects QoL and DoL in comparison
with healthy controls. In the second part, we prospect-
ively studied how the clinical progression of ALS affects
DoL and QoL. To the best of our knowledge, no study
in Spain has explored whether patients from an ALS
unit suffer a decline in QoL and DoL, nor the relation of
these with functional deterioration due to the disease.
Methods
Study design
We included patients who underwent routine follow-up
at our center between December 2015 and April 2016.
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The ALS unit at our center (UFELA) manages patients with
ALS from the Catalonia region, but mainly sees patients
from our hospital’s immediate catchment area containing
approximately 1.3 million people. First, we conducted a
cross-sectional observational study of patients with ALS
and compared them with 20 healthy controls. These latter
were selected from among the authors’ relatives (YMC, AL,
CH, RA, and DC) to present similar age and sex distribu-
tions, and were not excluded if they had non-complicated
high blood pressure, dyslipidemia, or diabetes. Second, we
performed a three-month prospective observational study
with a cohort of patients from the first part of the study,
who were being treated and followed up at our center for
diagnosed ALS. In total, three questionnaires were adminis-
tered: the ALSFR, the ALSAQ40, and the PDI.
Inclusion and exclusion criteria
All included patients signed and dated an informed con-
sent form and all had definitive ALS diagnosed accord-
ing to the El Escorial criteria [7]. The exclusion criteria
were cognitive impairment and motor neuron diseases
other than ALS, including primary lateral sclerosis, pro-
gressive muscular atrophy, progressive bulbar palsy, and
pseudobulbar palsy.
Assessment tools
Basic demographic and disease-specific data were obtained
for each patient, including their sex, current age, age of on-
set, time from symptom onset to diagnosis, region of onset
(spinal upper limbs, spinal lower limbs, bulbar, or respira-
tory), and the administration of symptomatic treatment
(PEG or BPAP). A control group of 20 healthy volunteers
was used for comparison. All participants (patients and
controls) completed the three study questionnaires at
baseline and after 3 months, and their progression
was evaluated by the difference in scores.
Statistical analysis
StataCorp Version 13.1 was used for statistical analysis.
Percentages (sex, use of PEG or BPAP, clinical onset)
and means (age at ALS onset and time for disease evolu-
tion) were used for descriptive analysis. Two-sample
Student t-tests with unequal variances were used to
compare the results of functional, QoL, and DoL param-
eters for the ALS and control groups. A p-value of ≤0.05
was taken as indicating statistical significance. In the
prospective study, mean scores were calculated for the
three questionnaires and the means obtained from the
two interviews were compared individually.
Results
Observational study
We evaluated 43 patients with ALS, whose mean age
was 60.33 years (Fig. 1a). Males predominated (53.5%),
the mean age at ALS onset was 56.67 years (range, 30–
75 years) (Fig. 1b), and the mean time for disease evolu-
tion was 39.16 months (range was between 9 and
124 months) (Fig. 1c). Nine patients (21%) required PEG,
15 (35%) required BPAP (Fig. 1c), and 4 required both.
Physical status, patient functionality, and QoL were
assessed with the ALSFR and ALSAQ40 scales, while dig-
nity was assessed with the PDI scale. All patients
responded to all the questionnaires. The median scores
obtained on the ALSFR, ALSAQ40, and PDI scales were
30.76 points (range, 12–47), 119.30 points (range, 52–
198), and 44.76 points (range, 28–66), respectively.
A significantly worse QoL was found in patients who
required BPAP or PEG (p= 0.0092 and P= 0.0108,
respectively). There were no significant differences in
sex by age (p = 0.7658), age of ALS onset (p = 0.6600),
clinical onset (p = 0.7059), duration of the disease (p
= 0.6181), need for PEG (p = 0.5559) or BIPAP (p =
0.5405), ALSFR (p = 0.9219), QoL (p = 0.5626), or DoL
(p = 0.4467). Neither were any significant differences
observed with regard to clinical onset and duration of
the disease (p = 0.1141), need for BIPAP (p = 0.6527),
ALSFR (p = 0.4888), QoL (p = 0.5742), or DoL(p = 0.9753).
Unsurprisingly, however, PEG was required more fre-
quently in patients with bulbar/respiratory onset than in
those with spinal onset (p = 0.0045). Similarly, no signifi-
cant differences were found in QoL or DoL by sex (p =
0.5626 and 0.4467, respectively), age of ALS onset (p =
0.3982 and 0.3325), clinical onset (spinal, p = 0.060 and
0.187; bulbar, p = 0.126 and 0.995; respiratory, p = 0.340
and 0.058), or disease duration (p = 0.660 and 0.3982).
There were no significant differences observed for PEG or
DoL (p = 0.5750).
The average age of the control cohort was 61.9 years
old, and males predominated (55%). The mean scores
and standard deviations on the ALSAQ40 and PDI
differed significantly (both p < 0.001) between the ALS
and control cohorts (Fig. 2a and b).
Prospective study
We followed up 23 patients with ALS over 3 months.
Most patients responded to both questionnaires, but 2
(8.7%) died from ALS-related respiratory failure before
finishing the study. There was a slight female predomin-
ance in the cohort (52.2%). The means for age, age of
onset, and time for disease evolution were 58.9 years,
54.7 years, and 3.66 years, respectively. Onset was bulbar
in 6 patients (26%), spinal in 15 (65.2%), and respiratory
in 2 (8.7%). Among those with spinal onset, 11 (47.8%)
were affected in the lower limbs first and 4 (17.4%)
in the upper limbs first. Ten patients (43.5%) started
BPAP and 6 (26%) started PEG over the three-month
study period.
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Clinical status
Patients’ clinical status and functionality, evaluated by
means of the ALSFR scale, showed significant worsening
from baseline (ALSFR scale1) to 3 months (ALSFR scale2),
with median scores of 30.95 and 27.24 points, respectively
(p= 0.0003; Fig. 3a).
Quality of life
The ALSAQ40 scale showed significant worsening from
baseline (ALSAQ40 scale1) to 3 months (ALSAQ40
scale2), with median scores of 124.19 and 131.81 points,
respectively (p = 0.0062; Fig. 3b).
Dignity of life
DoL, evaluated by means of the PDI scale, improved
slightly with disease progression, but no significant dif-
ferences were found between the scores at baseline (PDI
scale1) and 3 months (PDI scale2); the median scores
were 48.14 and 45 points, respectively (p = 0.12; Fig. 3c).
Discussion
All chronic diseases have major effects on QoL [7]. Patients
with chronic obstructive pulmonary disease, asthma, osteo-
arthritis, and stroke have all been shown to be at increased
risk of limitations to daily activities that are associated with
lower scores on QoL questionnaires. One of the most dis-
abling factors in these groups is depression [20, 21]. The
QoL scores of patients with progressive chronic diseases
also reportedly decrease with disease progression. Patients
with type I diabetes, for example, have significantly lower
QoL scores after 23.5 years’ follow-up as diabetes-related
complications and psychiatric events develop [22], while
patients with terminal cancer report significantly reduced
QoL scores in the last months of life [23].
In patients with neurological disorders such as multiple
sclerosis, there is a strong inverse correlation between
disability level and QoL test scores, with a close relationship
to depression and fatigue severity [21]. Similar patterns are
seen in ALS, with specific correlations between increased
physical dependency and depression, and between speech
impairment and anxiety [24]. The irremediable progression
of ALS tends to be reflected in a declining QoL. The goal
for clinicians and caregivers is to slow this progression and
render its impact less significant. These professionals must,
Fig. 1 a Distribution of age of onset in the sample. b Distribution of disease duration. c Use of PEG and BPAP
Fig. 2 a Statistical differences in ALSAQ40 between ALS patients
and the control cohort (p < 0.001). b Statistical differences in PDI
between ALS patients and the control cohort (p < 0.001)
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therefore, focus interventions on symptom control and pal-
liation, making decisions in the context of multidisciplinary
teams [11].
Although there are multiple references to QoL in chronic
progressive diseases [19], few studies mention DoL. How-
ever, dignity is an important concept that has recently
emerged as an important outcome measure for progressive,
degenerative conditions such as ALS, Huntington’s disease,
or Parkinson’s disease. The inability of clinicians to alter
disease progression significantly is sometimes taken to indi-
cate resignation to the fact that nothing more can be done;
but this is precisely why everything possible must be offered
to provide appropriate psychological support that upholds
patient dignity at all times [25, 26].
The epidemiological features of the patients in the obser-
vational part of this study were comparable to previously
reported studies; hence, we believe that our sample was
representative of patients with ALS. Unsurprisingly, pa-
tients reported worsening physical function, QoL, and DoL
in comparison with the healthy controls. This deterioration
did not seem to be associated with clinical or epidemio-
logical factors (onset, age of onset, or sex), but in contrast
with other studies [27, 28], the need to use technical aids
such as BPAP and PEG had a significant and negative asso-
ciation with the QoL of ALS patients. We consider that the
declines in QoL in these patients reflected disease progres-
sion more than the need to use the technical aid itself.
In the prospective study, after 3 months’ follow-up, statis-
tically significant declines were observed in both physical
function and QoL (measured by the ALSFR and ALSAQ40
scales, respectively), comparable to results in other studies
of QoL in patients with ALS [25, 26]. All the patients pre-
sented a certain degree of functional deterioration with a
mean worsening of 3.7 points on ALSFR. ALSFR ranges
from 0 to 40, so a drop of 3.7 points represents a significant
functional impact on the patients. Furthermore, a drop of 6
points on the ALSAQ40 scale (which ranges from 0 to 200)
shows a clear tendency toward worsening QoL, which
although slight, was already statistically significant in just
3 months of follow-up. However, despite significant deterio-
rations in these domains as the disease progressed, patients
did not show a decline in DoL, as measured by the PDI. In
fact, a slight non-significant increase in DoL was reported.
A possible explanation is that our center is staffed by skilled
nurses, psychologists, and caseworkers who provide psy-
chological support, prepare for future disease progression,
and encourage communication about end-of-life issues.
These factors have each been associated with higher DoL
scores, independently of disease progression [26]. Interdis-
ciplinary care is also known to be a significant factor in the
maintenance of dignity in patients with ALS [11], probably
due to the sense of security that is instilled by receiving care
from multiple specialists.
Unfortunately, there are limitations to this research.
Notably, the numbers of patients in the first (46) and
second [23] parts of the study, as well as the length of
follow-up time (3 months), were low, limiting the statis-
tical power of the study. However, this study included a
prospective component in which the number of patients
and follow-up period were sufficient to show statistically
significant changes. A future prospective study should
be designed with more patients followed over a longer
Fig. 3 a Comparison of patients’ clinical status at time 0 and at
3 months. b Comparison of patients’ quality of life at time 0 and at
3 months. c Comparison of patients’ dignity of life at time 0 and
at 3 months
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period to corroborate our results. We also chose not to
recruit relatives of ALS patients as controls to avoid the
potential bias of caregiver burnout. Instead, the healthy
control cohort was selected from among the relatives of
the study authors, matching by age and sex distribution.
Despite the valid justification, this could represent
another limitation.
Due to the considerable physical and emotional reper-
cussions of ALS, treatment should seek to improve QoL
and DoL in all patients [15, 23–25]. It is important that
we do not focus on traditional, disease-specific therapy,
but instead think about more general and contemporary
management principles. We believe that therapy focusing
on DoL and QoL may prove useful in many progressive
neurodegenerative conditions and other lethal diseases
that have no treatment [15, 25, 26].
Conclusions
ALS is a neurodegenerative disease that clearly affects
QoL and dignity. In this pilot study, we identified signifi-
cant deteriorations in clinical status, functionality, and
QoL, but not in DoL, as the disease progressed. It is likely
that this preservation of dignity is multifactorial in nature,
being closely related to the use of therapies derived from a
multidisciplinary approach to the disease. We believe that
DoL, not solely QoL, could be an important target in the
management of ALS.
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